BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8695969)

  • 1. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
    Agnusdei D; Gennari C; Bufalino L
    Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
    Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
    Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
    Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
    Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
    Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
    Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
    Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
    JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
    Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
    Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
    Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
    Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
    Orr-Walker BJ; Evans MC; Clearwater JM; Horne A; Grey AB; Reid IR
    Arch Intern Med; 2000 Jul; 160(14):2161-6. PubMed ID: 10904459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ipriflavone in established osteoporosis and long-term safety.
    Agnusdei D; Bufalino L
    Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
    Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials.
    Gallagher JC; Palacios S; Ryan KA; Yu CR; Pan K; Kendler DL; Mirkin S; Komm BS
    Menopause; 2016 Oct; 23(10):1083-91. PubMed ID: 27404034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
    Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Overgaard K; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
    Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
    Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.